Comparative Pharmacology
Head-to-head clinical analysis: KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE versus MECLOFENAMATE SODIUM.
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Ophthalmic: 1 drop of the combination (ketorolac tromethamine 0.45% and phenylephrine hydrochloride 1%) into the operative eye three times daily, beginning 1 day prior to surgery and continuing on the day of surgery and for 2 weeks postoperatively.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
Ketorolac: 2.4-8.6 hours (mean 5.3 hours) in young adults; prolonged in elderly (up to 13.9 hours) and renal impairment. Phenylephrine: 2-3 hours.
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Ketorolac: ~92% renal (60% as unchanged drug, 32% as metabolites), 6% fecal. Phenylephrine: primarily renal as metabolites (sulfate conjugates) with <1% unchanged.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category D/X
Category C
NSAID
NSAID